In a new study published in Frontiers in Veterinary Science, Wisdom Panel scientists have identified a genetic variant that significantly increases the risk of developing canine atopic dermatitis (cAD). The finding, centered on the SLAMF1 gene, is the first of its kind and could lead to informed breeding decisions.
The SLAMF1 variant was found in 71 percent of French Bulldogs and 40 percent of Boxers – breeds known to present frequently with this condition – significantly increasing their risk of developing cAD. The discovery came from analyzing clinical data from Banfield Pet Hospital paired with DNA data from Wisdom Panel.
Estimates suggest cAD affects up to 10 to 30 percent of dogs, and it is a condition with no known cure. These findings add vital knowledge to help improve understanding of disease processes and could potentially lead to more targeted solutions in the future. In addition, identification of the SLAMF1 variant presents the opportunity for breeders to breed toward dogs with a lower risk of atopic dermatitis.
Though the study specifically confirmed the link in French Bulldogs and Boxers, scientists believe the implications are much broader.
“This finding could have a real impact on dog health,” says Jimmy Barr, DVM, DACVECC, chief medical officer for Mars Petcare’s science and diagnostics division. “While atopy has long been suspected to have a genetic component, this is the first time the SLAMF1 gene has been convincingly linked to this debilitating skin condition. This knowledge will help identify dogs at risk and could lead to new therapies and more informed dog breeding practices.”
This research highlights Mars’ unique ability to leverage both scientific expertise and a wealth of data across its global Petcare ecosystem. In addition to Wisdom Panel and Banfield, this study is the first to leverage the MARS PETCARE BIOBANK, which functionally validated the study with samples. Additionally, the data was reviewed by expert dermatologists from Linnaeus.
But this isn’t just an academic win, the discovery has practical impact too. Wisdom Panel has developed a DNA test that will be offered in partnership with Canine Genetic Testing at the Department of Veterinary Medicine, University of Cambridge so breeders can benefit from this discovery, enabling them to make informed decisions to reduce the frequency of atopic dermatitis while maintaining genetic diversity.
